252 related articles for article (PubMed ID: 31310591)
1. Supraphysiological androgens suppress prostate cancer growth through androgen receptor-mediated DNA damage.
Chatterjee P; Schweizer MT; Lucas JM; Coleman I; Nyquist MD; Frank SB; Tharakan R; Mostaghel E; Luo J; Pritchard CC; Lam HM; Corey E; Antonarakis ES; Denmeade SR; Nelson PS
J Clin Invest; 2019 Jul; 129(10):4245-4260. PubMed ID: 31310591
[TBL] [Abstract][Full Text] [Related]
2. Supraphysiological Androgens Promote the Tumor Suppressive Activity of the Androgen Receptor through cMYC Repression and Recruitment of the DREAM Complex.
Nyquist MD; Coleman IM; Lucas JM; Li D; Hanratty B; Meade H; Mostaghel EA; Plymate SR; Corey E; Haffner MC; Nelson PS
Cancer Res; 2023 Sep; 83(17):2938-2951. PubMed ID: 37352376
[TBL] [Abstract][Full Text] [Related]
3. Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function.
Gui B; Gui F; Takai T; Feng C; Bai X; Fazli L; Dong X; Liu S; Zhang X; Zhang W; Kibel AS; Jia L
Proc Natl Acad Sci U S A; 2019 Jul; 116(29):14573-14582. PubMed ID: 31266892
[TBL] [Abstract][Full Text] [Related]
4. Targeting poly(ADP-ribose) polymerase and the c-Myb-regulated DNA damage response pathway in castration-resistant prostate cancer.
Li L; Chang W; Yang G; Ren C; Park S; Karantanos T; Karanika S; Wang J; Yin J; Shah PK; Takahiro H; Dobashi M; Zhang W; Efstathiou E; Maity SN; Aparicio AM; Li Ning Tapia EM; Troncoso P; Broom B; Xiao L; Lee HS; Lee JS; Corn PG; Navone N; Thompson TC
Sci Signal; 2014 May; 7(326):ra47. PubMed ID: 24847116
[TBL] [Abstract][Full Text] [Related]
5. Examining the Effect of PARP-1 Inhibitors on Transcriptional Activity of Androgen Receptor in Prostate Cancer Cells.
Makhov P; Fazliyeva R; Tufano A; Uzzo RG; Kolenko VM
Methods Mol Biol; 2023; 2609():329-335. PubMed ID: 36515844
[TBL] [Abstract][Full Text] [Related]
6. Dual roles of PARP-1 promote cancer growth and progression.
Schiewer MJ; Goodwin JF; Han S; Brenner JC; Augello MA; Dean JL; Liu F; Planck JL; Ravindranathan P; Chinnaiyan AM; McCue P; Gomella LG; Raj GV; Dicker AP; Brody JR; Pascal JM; Centenera MM; Butler LM; Tilley WD; Feng FY; Knudsen KE
Cancer Discov; 2012 Dec; 2(12):1134-49. PubMed ID: 22993403
[TBL] [Abstract][Full Text] [Related]
7. Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer.
Chuu CP; Kokontis JM; Hiipakka RA; Fukuchi J; Lin HP; Lin CY; Huo C; Su LC
J Biomed Sci; 2011 Aug; 18(1):63. PubMed ID: 21859492
[TBL] [Abstract][Full Text] [Related]
8. Selective androgen receptor modulators activate the canonical prostate cancer androgen receptor program and repress cancer growth.
Nyquist MD; Ang LS; Corella A; Coleman IM; Meers MP; Christiani AJ; Pierce C; Janssens DH; Meade HE; Bose A; Brady L; Howard T; De Sarkar N; Frank SB; Dumpit RF; Dalton JT; Corey E; Plymate SR; Haffner MC; Mostaghel EA; Nelson PS
J Clin Invest; 2021 May; 131(10):. PubMed ID: 33998604
[TBL] [Abstract][Full Text] [Related]
9. Androgen-dependent cell cycle arrest and apoptotic death in PC-3 prostatic cell cultures expressing a full-length human androgen receptor.
Heisler LE; Evangelou A; Lew AM; Trachtenberg J; Elsholtz HP; Brown TJ
Mol Cell Endocrinol; 1997 Jan; 126(1):59-73. PubMed ID: 9027364
[TBL] [Abstract][Full Text] [Related]
10. Androgen-independent LNCaP cells are a subline of LNCaP cells with a more aggressive phenotype and androgen suppresses their growth by inducing cell cycle arrest at the G1 phase.
Yu P; Duan X; Cheng Y; Liu C; Chen Y; Liu W; Yin B; Wang X; Tao Z
Int J Mol Med; 2017 Nov; 40(5):1426-1434. PubMed ID: 28901378
[TBL] [Abstract][Full Text] [Related]
11. Formononetin promotes cell cycle arrest via downregulation of Akt/Cyclin D1/CDK4 in human prostate cancer cells.
Li T; Zhao X; Mo Z; Huang W; Yan H; Ling Z; Ye Y
Cell Physiol Biochem; 2014; 34(4):1351-8. PubMed ID: 25301361
[TBL] [Abstract][Full Text] [Related]
12. TDP2 suppresses genomic instability induced by androgens in the epithelial cells of prostate glands.
Al Mahmud MR; Ishii K; Bernal-Lozano C; Delgado-Sainz I; Toi M; Akamatsu S; Fukumoto M; Watanabe M; Takeda S; Cortés-Ledesma F; Sasanuma H
Genes Cells; 2020 Jul; 25(7):450-465. PubMed ID: 32277721
[TBL] [Abstract][Full Text] [Related]
13. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
Murthy S; Agoulnik IU; Weigel NL
Prostate; 2005 Sep; 64(4):362-72. PubMed ID: 15754350
[TBL] [Abstract][Full Text] [Related]
14. Induction of DNA damage and p21-dependent senescence by Riccardin D is a novel mechanism contributing to its growth suppression in prostate cancer cells in vitro and in vivo.
Hu Z; Zhang D; Hao J; Tian K; Wang W; Lou H; Yuan H
Cancer Chemother Pharmacol; 2014 Feb; 73(2):397-407. PubMed ID: 24322375
[TBL] [Abstract][Full Text] [Related]
15. Supraphysiological androgen levels induce cellular senescence in human prostate cancer cells through the Src-Akt pathway.
Roediger J; Hessenkemper W; Bartsch S; Manvelyan M; Huettner SS; Liehr T; Esmaeili M; Foller S; Petersen I; Grimm MO; Baniahmad A
Mol Cancer; 2014 Sep; 13():214. PubMed ID: 25216853
[TBL] [Abstract][Full Text] [Related]
16. Cryptotanshinone suppresses androgen receptor-mediated growth in androgen dependent and castration resistant prostate cancer cells.
Xu D; Lin TH; Li S; Da J; Wen XQ; Ding J; Chang C; Yeh S
Cancer Lett; 2012 Mar; 316(1):11-22. PubMed ID: 22154085
[TBL] [Abstract][Full Text] [Related]
17. 6-(3,4-Dihydro-1H-isoquinoline-2-yl)-N-(6-methoxypyridine-2-yl) nicotinamide-26 (DIMN-26) decreases cell proliferation by induction of apoptosis and downregulation of androgen receptor signaling in human prostate cancer cells.
Choi HE; Shin JS; Leem DG; Kim SD; Cho WJ; Lee KT
Chem Biol Interact; 2016 Dec; 260():196-207. PubMed ID: 27720946
[TBL] [Abstract][Full Text] [Related]
18. Androgen receptor activity in prostate cancer dictates efficacy of bipolar androgen therapy through MYC.
Sena LA; Kumar R; Sanin DE; Thompson EA; Rosen DM; Dalrymple SL; Antony L; Yang Y; Gomes-Alexandre C; Hicks JL; Jones T; Bowers KA; Eskra JN; Meyers J; Gupta A; Skaist A; Yegnasubramanian S; Luo J; Brennen WN; Kachhap SK; Antonarakis ES; De Marzo AM; Isaacs JT; Markowski MC; Denmeade SR
J Clin Invest; 2022 Dec; 132(23):. PubMed ID: 36194476
[TBL] [Abstract][Full Text] [Related]
19. Difference in protein expression profile and chemotherapy drugs response of different progression stages of LNCaP sublines and other human prostate cancer cells.
Lin HP; Lin CY; Hsiao PH; Wang HD; Jiang SS; Hsu JM; Jim WT; Chen M; Kung HJ; Chuu CP
PLoS One; 2013; 8(12):e82625. PubMed ID: 24349321
[TBL] [Abstract][Full Text] [Related]
20. PARP Inhibitors in Prostate Cancer—The Preclinical Rationale and Current Clinical Development.
Virtanen V; Paunu K; Ahlskog JK; Varnai R; Sipeky C; Sundvall M
Genes (Basel); 2019 Jul; 10(8):. PubMed ID: 31357527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
